NCT00003489 - Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 1996

Primary Completion Date

April 3, 1998

Study Completion Date

April 3, 1998

Conditions

Head and Neck Cancer

Interventions

DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston